NCT06934499

Brief Summary

This is a prospective, multicenter, observational, national study. Eligible patients will be recruited consecutively among subjects with proven lung cancer, including any disease stage withclinical, therapeutic and evolutive discription.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,334

participants targeted

Target at P75+ for all trials

Timeline
6mo left

Started May 2025

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress68%
May 2025Oct 2026

First Submitted

Initial submission to the registry

April 11, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 18, 2025

Completed
14 days until next milestone

Study Start

First participant enrolled

May 2, 2025

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2026

Expected
Last Updated

June 4, 2025

Status Verified

June 1, 2025

Enrollment Period

6 months

First QC Date

April 11, 2025

Last Update Submit

June 2, 2025

Conditions

Pulmonary Cancer

Keywords

Pulmonary CancerRegistryTunisia

Outcome Measures

Primary Outcomes (3)

  • Diagnostic delay

    Delay to set the pulmonary cancer diagnosis

    Day 1

  • Survival

    Overall survival

    12 months

  • Relapse

    Time to relapse

    12 months

Secondary Outcomes (1)

  • Recommendation Compliance

    Day 1

Other Outcomes (1)

  • Multidisciplinary Consultation Meetings

    12 months

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All participants diagnosed with histologically confirmed lung cancer will be included in the study, regardless of sex, age, stage and histological subtype. Patients will be enrolled in the study consecutively The study will be conducted in different regions of Tunisia, encompassing several sites covering different departments in public hospitals.

You may qualify if:

  • Age more than 18 years
  • Informed consent

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Tunisian Society of Medical Oncology

Aryanah, 2080, Tunisia

NOT YET RECRUITING

Tunisian Society of Respiratory Diseases and Allergology

Tunis, Tunisia

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Soraya Fenniche, MD

    Multidisciplinary consultation meeting Thoracic of the Abderrahmen Mami ROTHA Hospital

    STUDY CHAIR

  • Nesrine Mejri, MD

    Multidisciplinary consultation meeting Thoracic of the Abderrahmen Mami ROTHA Hospital

    STUDY CHAIR

Central Study Contacts

Soraya Fenniche, MD

CONTACT

+216 98 586 490soraya.fenniche@yahoo.fr

Nesrine Mejri, MD

CONTACT

+216 97 429 933nesrinemejriturki2@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 11, 2025

First Posted

April 18, 2025

Study Start

May 2, 2025

Primary Completion

October 30, 2025

Study Completion (Estimated)

October 30, 2026

Last Updated

June 4, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations

TU(2)